4-hexylresorcinol inhibits NF-κB phosphorylation and has a synergistic effect with cisplatin in KB cells

Oncology Reports

Volumn 26, Issue 6, 2011, Pages 1527-1532

  Kim, Seong Gon ^a   Lee, Sang Woon ^a   Park, Young Wook ^a   Jeong, Jae Hwan ^b   Choi, Je Yong ^b  

^a Gangneung Wonju National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

4 hexylresorcinol; Cisplatin; Nuclear factor b; Squamous cell carcinoma

Indexed keywords

CISPLATIN; HEXYLRESORCINOL; I KAPPA B; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL STRAIN KB; DISEASE DURATION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; GENE ACTIVATION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; TUMOR; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WEIGHT REDUCTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL NUCLEUS; CISPLATIN; DRUG SYNERGISM; GTP-BINDING PROTEINS; HEXANES; HUMANS; I-KAPPA B KINASE; IMMUNOPRECIPITATION; MALE; MICE; MICE, NUDE; NF-KAPPA B; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TRANSPORT; RANDOM ALLOCATION; RESORCINOLS; TRANSGLUTAMINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053472490     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1436     Document Type: Article

References (38)

1. Fanucchi M and Khuri FR: Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol 31: 809-815, 2004.
2. Forshaw MJ, Gossage JA and Mason RC: Neoadjuvant chemotherapy for oesophageal cancer: the need for accurate response prediction and evaluation. Surgeon 3: 373-382, 2005.
3. Touboul E, Lefranc JP, Blondon J, et al: Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery. Radiother Oncol 25: 167-175, 1992.
4. Mak RH, Halasz LM, Tanaka CK, et al: Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva. Gynecol Oncol 120: 101-107, 2011.
5. Beer TM and Bubalo JS: Prevention and management of prostate cancer chemotherapy complications. Urol Clin North Am 31: 367-378, 2004.
6. Singh N, Scully C and Joyston-Bechal S: Oral complications of cancer therapies: prevention and management. Clin Oncol (R Coll Radiol) 8: 15-24, 1996.
7. Zinzani PL: Complications of cytotoxic chemotherapy in older patients: focus on myelotoxicity in lymphomas. Crit Rev Oncol Hematol 48 (Suppl): S27-S31, 2003.
8. Kennedy L and Diamond J: Assessment and management of chemotherapy-induced mucositis in children. J Pediatr Oncol Nurs 14: 164-174, 1997.
9. Lokich J, Anderson N, Bern M, et al: Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer. Eur J Cancer 34: 659-663, 1998.
10. Zhu Y, Hu J, Hu Y and Liu W: Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance. Cancer Treat Rev 35: 590-596, 2009.
11. West KA, Castillo SS and Dennis PA: Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5: 234-248, 2002.
12. Tergaonkar V, Pando M, Vafa O, Wahl G and Verma I: p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 1: 493-503, 2002.
13. Mann AP, Verma A, Sethi G, et al: Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res 66: 8788-8795, 2006.
14. Kim DS, Han BG, Park KS, Lee BI, Kim SY and Bae CD: I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway. Biochem Biophys Res Commun 399: 300-306, 2010.
15. Jacobs MD and Harrison SC: Structure of an IkappaBalpha/NF-kappaB complex. Cell 95: 749-758, 1998.
16. Matthews JR and Hay RT: Regulation of the DNA binding activity of NF-κB. Int J Biochem Cell Biol 27: 865-879, 1995.
17. Gupta SC, Sundaram C, Reuter S and Aggarwal BB: Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 1799: 775-787, 2010.
18. Orlowski RZ and Baldwin AS Jr: NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8: 385-389, 2002.
19. Iyidogan NF and Bayindirli A: Effect of l-cysteine, kojic acid and 4-hexylresorcinol combination on inhibition of enzymatic browning in Amasya apple juice. J Food Eng 62: 299-304, 2003.
20. Martínez-Alvarez O, López-Caballero ME, Montero P and Gómez-Guillén MC: Spraying of 4-hexylresorcinol based formulations to prevent enzymatic browning in Norway lobsters (Nephrops norvegicus) during chilled storage. Food Chem 100: 147-155, 2007.
21. National Toxicology Program: NTP Toxicology and Carcinogenesis Studies of 4-Hexylresorcinol (CAS No. 136-77-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser 330: 1-166, 1988.
22. Rabbani GH, Gilman RH, Kabir I and Mondel G: The treatment of Fasciolopsis buski infection in children: a comparison of thiabendazole, mebendazole, levamisole, pyrantel pamoate, hexylresorcinol and tetrachloroethylene. Trans R Soc Trop Med Hyg 79: 513-515, 1985.
23. Pink R, Hudson A, Mouriès MA and Bendig M: Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov 4: 727-740, 2005.
24. Horton J: Global anthelmintic chemotherapy programs: learning from history. Trends Parasitol 19: 405-409, 2003.
25. Dieter MP, Jameson CW, French JE, et al: Development and validation of a cellular transplant model for leukemia in Fischer rats: a short-term assay for potential anti-leukemic chemicals. Leuk Res 13: 841-849, 1989.
26. Kim SG, Jeong JH, Park YW, et al: 4-Hexylresorcinol inhibits transglutaminase-2 activity and has synergistic effects along with cisplatin in KB cells. Oncol Rep 25: 1597-1602, 2011.
27. Park YW, Kim SG, Choi JY and Lee SK: Recapitulating orthotopic tumor model through establishment of a parotid gland tumor with lung metastasis using HeLa cell injection into nude mice. Oncol Rep 23: 701-708, 2010.
28. Carlsson G, Gullberg B and Hafström L: Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 105: 20-23, 1983.
29. Hand D, Bungay PJ, Elliott BM and Griffin M: Activation of transglutaminase at calcium levels consistent with a role for this enzyme as a calcium receptor protein. Biosci Rep 5: 1079-1086, 1985.
30. Achyuthan KE and Greenberg CS: Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. J Biol Chem 262: 1901-1906, 1987.
31. Burstein E and Duckett CS: Dying for NF-kappaB? Control of cell death by transcriptional regulation of the apoptotic machinery. Curr Opin Cell Biol 15: 732-737, 2003.
32. Radhakrishnan SK and Kamalakaran S: Pro-apoptotic role of NF-kappaB: implications for cancer therapy. Biochim Biophys Acta 1766: 53-62, 2006.
33. Mehta K, Kumar A and Kim HI: Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol 80: 1921-1929, 2010.
34. Verma A and Mehta K: Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat 10: 144-151, 2007.
35. Olivier S, Robe P and Bours V: Can NF-kappaB be a target for novel and efficient anti-cancer agents? Biochem Pharmacol 72: 1054-1068, 2006.
36. Malinge JM, Giraud-Panis MJ and Leng M: Interstrand cross-links of cisplatin induce striking distortions in DNA. J Inorg Biochem 77: 23-29, 1999.
37. Jamshidipour R, Pinho EB and Howell SB: In vivo modulation of cisplatin cytotoxicity by the chelcystokinin antagonist MK-329 in human pancreatic cancer xenografts. Anticancer Res 14: 2611-2616, 1994.
38. Nam NH: Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem 6: 945-951, 2006.